Abstract 73P
Background
Subclinical hypothyroidism (SH) has been reported in some chronic myeloid leukaemia (CML) patients on Imatinib mesylate. However, the risk of developing this thyroid dysfunction while on Imatinib has not been elucidated. Therefore, we investigated the baseline parameters of the CML patients as predictor of thyroid dysfunction in BCR::ABL1-positive CML patients.
Methods
This was a longitudinal study that included 50 imatinib naïve BCR::ABL1-positive CML patients. Serum TSH, fT3 and fT4 were done for each patient at recruitment and at 1, 3 and 6 months on imatinib therapy. All analyses were done by the automated Cobas E 411 analyzer (Roche Diagnostics GmbH, SandhoferStrasse 116, D-68305 Mannheim, Germany. These patients were classified into 2 groups based on the TFT results i.e. CML1, patients who remained euthyroid and CML2, those who developed subclinical hypothyroidism at 6 months on Imatinib therapy. Basic and inferential statistical were used to determine the mean difference between the baseline characteristics (Age, PCV, Sokal, Hasford and EUTO scores) of CML1 and CML 2 and to determine the relationship between these baseline parameters and the serum TSH. The alpha value was set as < 0.05.
Results
Serum TSH was found to be elevated in 7 (14%) of the patients ( 6 females and 1 male) at 6 months only, while the serum fT3 and fT4 were consistently within the reference interval and this is consistent with the diagnosis of subclinical hypothyroidism while 43 patients remained euthyroid. The mean ages ± SD in years of the two groups (CML1 vs CML 2) were (36.26 ± 10.97 vs 44.71 ± 11.10 t=-1.889, p-value=0.065). The mean PCV ± SD of the two groups (28.67 ± 5.54 vs24.00 ± 4.80 t=2.121, p-value=0.039*) and the mean Sokal score ± SD (CML1 vs CML 2) were (0.94 ± 0.31 vs 1.25 ± 0.61 t=-2.061, p-value=0.045*) while the mean Hasford score ± SD (CML1 vs CML 2) were (927.09 ± 488.17 vs 1426.25 ± 630.45 t=-2.410, p-value=0.020*) and EUTO score (80.91 ± 57.29 vs 102.00 ± 56.19 t=-0.906, p-value=0.370). Sokal score showed positive correlation and the only parameter with statistical significance with TSH (r=0.399, p- value=0.039*).
Conclusions
This study has reported that imatinib could induce SH in CML patients and baseline Sokal score could be a predictor.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr. Ahmed Ibrahim.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.